Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely watched innovative…
This is a brief. The reporting belongs to South China Morning Post — read the complete story, with full context and credits, at the source.
Read the full story at South China Morning Post ↗scmp.com
More from the World desk
Just in
Mother of five children killed in house fire tells inquest 'fire was everywhere'
Just in

Bid to marry off pregnant girl, 12, in Malaysia leads to man’s arrest
Just in

Wife of assassinated ex-Haitian leader registers for presidential election
Just in

HD Hyundai Heavy wins 272 bln-won order for 4 LPG carriers
Just in
